A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study. (Q45923193)

From Wikidata

Jump to navigation Jump to search

scientific article published on 19 December 2013

Language	Label	Description	Also known as
English	A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study.	scientific article published on 19 December 2013

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24352251

A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): a Galician Lung Cancer Group (GGCP) study. (English)

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24352251

chemoradiotherapy

0 references

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

author name string

J Casal Rubio

1

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24352251

J L Fírvida-Pérez

2

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24352251

M Lázaro-Quintela

3

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24352251

F J Barón-Duarte

4

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24352251

G Alonso-Jáudenes

5

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24352251

L Santomé

6

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24352251

F J Afonso-Afonso

7

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24352251

M Amenedo

8

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24352251

G Huidobro

9

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24352251

B Campos-Balea

10

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24352251

M D López-Vázquez

11

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24352251

S Vázquez

12

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24352251

publication date

19 December 2013

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24352251

Cancer Chemotherapy and Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24352251

73

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24352251

3

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24352251

451-457

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24352251

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2370-Z

21 January 2018

Lung cancer: New biological insights and recent therapeutic advances

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2370-Z

21 January 2018

Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2370-Z

21 January 2018

Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2370-Z

21 January 2018

Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2370-Z

21 January 2018

Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2370-Z

21 January 2018

Phase III study comparing second- and third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2370-Z

21 January 2018

[Targeted therapies and radiation therapy in non-small cell lung cancer].

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2370-Z

21 January 2018

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2370-Z

21 January 2018

Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2370-Z

21 January 2018

EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2370-Z

21 January 2018

Combination of radiotherapy and targeted therapies in the treatment of locally advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2370-Z

21 January 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2370-Z

21 January 2018

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2370-Z

21 January 2018

Phase II study of docetaxel and carboplatin in elderly patients with advanced non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2370-Z

21 January 2018

Maintenance therapy in NSCLC: why? To whom? Which agent?

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2370-Z

21 January 2018

A randomized phase III trial of combined paclitaxel, carboplatin, and radiation therapy followed by weekly paclitaxel or observation for patients with locally advanced inoperable non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2370-Z

21 January 2018

Consolidation Docetaxel After Concurrent Chemoradiotherapy in Stage IIIB Non–Small-Cell Lung Cancer: Phase II Southwest Oncology Group Study S9504

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2370-Z

21 January 2018

Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2370-Z

21 January 2018

Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023.

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2370-Z

21 January 2018

Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00280-013-2370-Z

21 January 2018

Identifiers

10.1007/S00280-013-2370-Z

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24352251

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

17 December 2017

http://europepmc.org/abstract/MED/24352251

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45923193&oldid=2249142285"